Pharmacogenetics of acenocoumarol pharmacodynamics

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 5, 2004, Pages 403-414

  Morin, Sandrine ^b   Bodin, Laurent ^b   Loriot, Marie Anne ^b   Thijssen, Henk H W ^b   Robert, Annie ^b   Strabach, Soraya ^b   Verstuyft, Céline ^b   Tregouet, David Alexandre ^b   Dubert, Liliane ^b   Laurent Puig, Pierre ^b   Funck Brentano, Christian ^b   Jaillon, Patrice ^b   Beaune, Philippe H ^b   Becquemont, Laurent ^a  

^a BICÊTRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; BLOOD CLOTTING FACTOR 8; CYTOCHROME P450 2C9; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADULT; AGED; ALLELE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA FLANKING REGION; DRUG ABSORPTION; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ALLELES; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; DNA PRIMERS; FACTOR VII; FEMALE; FRANCE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 11144353744     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.01.008     Document Type: Article

References (36)

1. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding clinical epidemiology, prediction, and prevention. Am J Med. 95:1993;315-328
2. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 287:2002;1690-1698
3. Daly A.K., King B.P. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 13:2003;247-252
4. Verstuyft C., Robert A., Morin S., Loriot M.A., Beaune P., Funck-Brentano C., et al. Genetic and environmental risk factors for oral anticoagulant overdose. Eur J Clin Pharmacol. 58:2003;739-745
5. Meinertz T., Kasper W., Kahl C., Jahnchen E. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol. 5:1978;187-188
6. Thijssen H.H., Flinois J.P., Beaune P.H. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos. 28:2000;1284-1290
7. Tassies D., Freire C., Pijoan J., Maragall S., Monteagudo J., Ordinas A., et al. Pharmacogenetics of acenocoumarol cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica. 87:2002;1185-1191
8. Hermida J., Zarza J., Alberca I., Montes R., Lopez M.L., Molina E., et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood. 99:2002;4237-4239
9. Aithal G.P., Day C.P., Kesteven P.J., Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719
10. Thijssen H., Verkooijen I., Frank H. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics. 10:2000;757-760
11. Ingelman-Sundberg M, Daly AK, Nebert DW. Human cytochrome P450 allele nomenclature. Available from: URL: http://www.imm.ki.se/CYPalleles/. Accessed March 18, 2004
12. Shintani M., Ieiri I., Inoue K., Mamiya K., Ninomiya H., Tashiro N., et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene in vitro and in vivo studies. Clin Pharmacol Ther. 70:2001;175-182
13. Margaglione M., Colaizzo D., Andrea G., Brancaccio V., Ciampa A., Grandone E., et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 84:2000;775-778
14. Taube J., Halsall D., Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 96:2000;1816-1819
15. Verstuyft C., Morin S., Robert A., Loriot M.A., Beaune P., Jaillon P., et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics. 11:2001;735-737
16. Goldstein D.B. Pharmacogenetics in the laboratory and the clinic. N Engl J Med. 348:2003;553-556
17. Nebert D.W., Roe A.L., Vandale S.E., Bingham E., Oakley G.G. NAD(P)H quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med. 4:2002;62-70
18. Wallin R., Martin L.F. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 76:1985;1879-1884
19. Gardill S.L., Suttie J.W. Vitamin K epoxide and quinone reductase activities. Evidence for reduction by a common enzyme. Biochem Pharmacol. 40:1990;1055-1061
20. Stubbins M.J., Harries L.W., Smith G., Tarbit M.H., Wolf C.R. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 6:1996;429-439
21. Morin S., Loriot M.A., Poirier J.M., Tenneze L., Beaune P.H., Funck-Brentano C., et al. Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol. 56:2001;793-797
22. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients genetic analysis of the CYP2C9 locus. Pharmacogenetics. 10:2000;85-89
23. Dickmann L.J., Rettie A.E., Kneller M.B., Kim R.B., Wood A.J., Stein C.M., et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 60:2001;382-387
24. Ellis L.A., Taylor C.F., Taylor G.R. A comparison of fluorescent SSCP and denaturing HPLC for high throughput mutation scanning. Hum Mutat. 15:2000;556-564
25. DHPLC melt program. Available from: URL: http://insertion.stanford.edu/ melt.html. Accessed July 7, 2003
26. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., Greaves M.F. A lack of a functional NAD(P)H quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 59:1999;4095-4099
27. Aiach M., Fiessinger J.N., Capron L., Nussas C., Housset E., Leclerc M. Kinetic study of factor X during oral anticoagulation with acenocoumarol potential value for the initiation of treatment. Thromb Haemost. 47:1982;69-71
28. Thijssen H.H., Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther. 74:2003;61-68
29. Tregouet D.A., Barbaux S., Escolano S., Tahri N., Golmard J.L., Tiret L., et al. Specific haplotypes of the P-selectin gene are associated with myocardial infarction. Hum Mol Genet. 11:2002;2015-2023
30. Nei M. Molecular evolutionary genetics. 1987;Columbia University Press, New York
31. Elbein S.C. Linkage disequilibrium among RFLPs at the insulin-receptor locus despite intervening Alu repeat sequences. Am J Hum Genet. 51:1992;1103-1110
32. Kirchheiner J., Stormer E., Meisel C., Steinbach N., Roots I., Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 13:2003;473-480
33. Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I., et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S, 5R-fluvastatin and (+)-3R, 5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 74:2003;186-194
34. Kirchheiner J., Brockmoller J., Meineke I., Bauer S., Rohde W., Meisel C., et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 71:2002;286-296
35. King B.P., Khan T., Kamali F., Daly A.K. Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirement. abstract Drug Metab Rev. 35:2003;133
36. Yang J.Q., Morin S., Verstuyft C., Fan L.A., Zhang Y., Xu C.D., et al. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol. 17:2003;373-376